Ignite Proteomics
About Ignite Proteomics
Ignite Proteomics is a company founded in 2024 was acquired by Aditx Therapeutics in March 2026. It operates as a B2B. Ignite Proteomics offers products and services including 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection. Ignite Proteomics operates in a competitive market with competitors including Personalis, OncoDNA, Ultivue, Strata Oncology and RootPath Genomics, among others.
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Aditx Therapeutics
(Mar 13, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ignite Proteomics
Ignite Proteomics offers a comprehensive portfolio of products and services, including 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection.
Assists physicians with data-driven treatment decisions using protein biomarkers.
Enables proteome assessment for oncology therapeutic development.
Supports targeted proteome analysis in clinical trials.
Funding Insights of Ignite Proteomics
Detailed funding history for Ignite Proteomics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Ignite Proteomics
Ignite Proteomics has secured backing from 1 investor. Prominent investors backing the company include Aditx Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Immune monitoring solutions are provided to the medical community.
|
Locked | Locked | Locked |
Investor details for Ignite Proteomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ignite Proteomics
Investment portfolio details for Ignite Proteomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ignite Proteomics
Detailed financials for Ignite Proteomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ignite Proteomics Comparisons
Peer comparison for Ignite Proteomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ignite Proteomics
Ignite Proteomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Personalis, OncoDNA, Ultivue, Strata Oncology and RootPath Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Provider of test panels for personalized cancer therapies
|
|
| Locked | Locked | Locked |
Genetic sequencing is provided for late-stage cancer patients.
|
|
| Locked | Locked | Locked |
Immunotherapy platform is developed for personalized cancer treatment.
|
|
| Locked | Locked | Locked |
Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis.
|
Detailed competitors of Ignite Proteomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ignite Proteomics
Complete news archive for Ignite Proteomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ignite Proteomics
Ignite Proteomics was founded in 2024.
Ignite Proteomics specializes in proteomics through a 32-analyte assay that aids physicians in data-driven treatment decisions for oncology. It supports BioPharma partners by using techniques like Reverse Phase Protein Array and laser capture microdissection for therapeutic development. The company focuses on predictive protein biomarkers and collaborates with healthcare professionals.
Ignite Proteomics's top competitors include Personalis, OncoDNA and ACT Genomics.
Ignite Proteomics offers 32-analyte Assay, Reverse Phase Protein Array, and Laser Capture Microdissection.
Ignite Proteomics has 1 investor. Key investors include Aditx Therapeutics.